Ignite Creation Date:
2024-05-06 @ 1:16 PM
Last Modification Date:
2024-10-26 @ 1:11 PM
Study NCT ID:
NCT03970382
Status:
SUSPENDED
Last Update Posted:
2022-08-18
First Post:
2019-05-06
Brief Title:
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
Sponsor:
PACT Pharma Inc
Organization:
PACT Pharma Inc
Study Overview
Official Title:
A Phase 1a1b Open-label First-in-human Study of the Safety Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells NeoTCR-P1 Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
Status:
SUSPENDED
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Business decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first in human single arm open label Phase 1a1b study to determine the safety feasibility and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None